In order to expand its oncology portfolio, Pyxis Oncology has entered into a definite agreement to acquire Apexigen in an all-stock deal for a total value of US$16 M. Through this deal, Pyxis will gain access to Apexigen’s APXiMAB™ discovery platform along with its lead oncology asset, sotigalimab. Following the transaction, Apexigen will become a wholly owned subsidiary of Pyxis. The therapeutic potential of Apexigen’s antibody platform will be greatly increased when combined with Pyxis’ complimentary antibody-drug conjugate technology platform.